New shot could tame hay fever symptoms for good
NCT ID NCT07154342
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 3 trial tests an injection called GR1802 for people with seasonal allergic rhinitis (hay fever) that is not well controlled by standard treatments. The drug is a lab-made antibody that blocks a key inflammation signal. About 150 adults will receive either GR1802 or a placebo, plus their usual allergy meds, to see if it reduces nasal and eye symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GR1802 injection (a lab-made antibody that blocks a protein involved in allergy inflammation)
- What this could lead to
- If it works, this could offer a new option for people with seasonal allergies that are not well controlled by current treatments like nasal sprays.
- What could go wrong
- This is still an early Phase 3 trial with only 150 participants, so results may not apply to everyone. The drug is an injection and may have side effects like injection site reactions or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC RHINITIS, SEASONAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongnan Hospital of Wuhan university
RECRUITINGWuhan, Hubei, 430000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.